Pomgulated methionil (LY2140023) in schizophrenia patients: a systematic review and meta-analysis

Pomaglumetad methionil (LY2140023 monohydrate) is a potent and selective agonist for metabotropic glutamate receptors (mGluR2/3). Unlike traditional antipsychotics, it does not directly interact with dopamine or serotonin (5-HT2A) receptors, potentially offering a novel mechanism of action with a different side-effect profile. We aim to provide an overview of this novel drug and evaluate its efficacy in comparison to both placebo and atypical antipsychotics by performing a systematic review and meta-analysis.

A comprehensive literature search was conducted to identify relevant studies. The included studies investigated the effect of Promogulated methionil. The quality of studies was assessed using the Cochrane Risk of Bias 2 (ROB-2) Statistical analysis was conducted using Review Manager (revman) with outcomes expressed as Mean differences (MD) with 95% confidence intervals (CI).

The systematic review included 4 randomized clinical trials (RCTs). The analysis revealed that pomaglumetad methionil (LY2140023) didn't have a statistically significant effect on PANNS compared to placebo (p-value = 0.31) and it was less effective in decreasing PANSS score in comparison to atypical antipsychotics (p-value < 0.00001). However, the drug showed a significant effect on weight gain (p-value < 0.00001) and prolactin (p < 0.0001) in comparison to atypical antipsychotics.

In conclusion, this systematic review and meta-analysis provide evidence that pomaglumetad methionil (LY2140023) does not demonstrate consistent efficacy in the treatment of schizophrenia. Although the compound is associated with a more favorable profile regarding weight gain and prolactin elevation, these advantages do not compensate for its lack of therapeutic efficacy.